|
|
Notice: Agency Information Collection Activities; Proposed Collection;
Comment Request; Export of Medical Devices-Foreign Letters of Approval Federal Register: January 26, 2010 (Volume 75, Number 16)
Page 4086-4087AGENCY: Food and Drug Administration.
ACTION: Notice.
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on reporting requirements for
firms that intend to export certain unapproved medical devices.
DATES: Submit written or electronic comments on the collection of
information by March 29, 2010.
ADDRESSES: Submit electronic comments on the collection of information
to http://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Daniel Gittleson, Office of
Information Management (HFA-710), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-796-5156,
Daniel.Gittleson@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information before
submitting the collection to OMB for approval. To comply with this
requirement, FDA is publishing notice of the proposed collection of
information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Export of Medical Devices-Foreign Letters of Approval (OMB Control
Number 0910-0264)--Extension
Section 801(e)(2) of the Federal Food, Drug, and Cosmetic Act (the
act) (21 U.S.C. 381(e)(2)) provides for the exportation of an
unapproved device under certain circumstances if the exportation is not
contrary to the public health and safety and it has the approval of the
foreign country to which it is intended for export.
Requesters communicate (either directly or through a business
associate in the foreign country) with a representative of the foreign
government to which they seek exportation, and written authorization
must be obtained from the appropriate office within the foreign
government approving the importation of the medical device. An
alternative to obtaining written authorization from the foreign
government is to accept a notarized certification from a responsible
company official in the United States that the product is not in
conflict with the foreign country's laws. This certification must
include a statement acknowledging that the responsible company official
making the certification is subject to the provisions of 18 U.S.C.
1001. This statutory provision makes it a criminal offense to knowingly
and willingly make a false or fraudulent statement, or make or use a
false document, in any manner within the jurisdiction of a department
or agency of the United States.
The respondents to this collection of information are companies
that seek to export medical devices.
FDA estimates the burden of this collection of information as
follows:
[[Page 4087]]
Table 1.--Estimated Annual Reporting Burden\1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Section of the Federal Food, Drug, and Cosmetic Annual Frequency Total Annual Hours per
Act No. of Respondents per Response Responses Response Total Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
801(e)(2) 38 1 38 3 114
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
FDA's estimate of the reporting burden is based on the experience
of FDA's medical device program personnel.
Dated: January 20, 2010.
David Dorsey,
Acting Deputy Commissioner for Policy, Planning and Budget.
[FR Doc. 2010-1438 Filed 1-25-10; 8:45 am]
BILLING CODE 4160-01-S |